Skip to main content

Advertisement

Table 3 The Cox proportional hazards model of progression-free survival in synchronous and metachronous mRCC group

From: Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis

  Synchronous mRCC (N = 144 /EVENT = 130) Metachronous mRCC (N = 70/EVENT = 63)
Univariable Multivariable Univariable Multivariable
Hazard ratio
(95% CI)
P-value Hazard ratio
(95% CI)
P-value Hazard ratio
(95% CI)
P-value Hazard ratio
(95% CI)
P-value
Risk group Intermediate 1     1    
poor 1.728 (1.156–2.584) 0.0077    1.801 (0.766–4.235) 0.1772   
Therapy IT 1   1   1   1  
TT 1.858 (1.288–2.681) 0.0009 1.696 (1.157–2.486) 0.0068 2.019 (1.202–3.39) 0.0079 2.019 (1.202–3.39) 0.0079
Treatment Free interval ≥1 yr 1     1    
< 1 yr 1.017 (0.473–2.184) 0.9660    1.752 (0.995–3.084) 0.052   
Gender Male 1     1    
Female 1.215 (0.777–1.901) 0.3934    1.155 (0.670–1.993) 0.6041   
Age (year)   0.991 (0.975–1.007) 0.2801    0.980 (0.951–1.009) 0.1692   
Anemia Normal 1     1    
Hb < 13.5(male)/12.0(Female) 1.724 (1.142–2.600) 0.0095    0.846 (0.427–1.675) 0.6311   
Hypercalcemia Normal 1     1    
> 10 mg/dL or 2.5 mmol/L 1.166 (0.705–1.929) 0.5499    0.995 (0.444–2.227) 0.9897   
Neutrophilia Normal 1   1   1    
< 1500 or > 7500 2.497 (1.53–4.074) 0.0002 2.105 (1.274–3.478) 0.0037 0.918 (0.464–1.817) 0.806   
Elevated LDH Normal 1     1    
1.5 X ULN 1.482 (0.943–2.329) 0.0883    1.491 (0.661–3.365) 0.3357   
KPS >  80 1        
≤ 80 2.122 (0.779–5.779) 0.1409       
Thrombocytosis Normal 1     1    
> 400 K 1.700 (1.013–2.855) 0.0448    1.054 (0.379–2.932) 0.9199